Eisai Seeks Accelerated FDA Approval of Alzheimer’s Drug Despite Medicare Decision

Published on April 8, 2022

Eisai Co Ltd on Friday said it still planned to seek an accelerated U.S. approval pathway for its experimental Alzheimer’s drug even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner. On Thursday, after a months-long…

Read Full Article (External Site)